Literature DB >> 2666594

Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors.

A Twijnstra1, B W Ongerboer de Visser, A P van Zanten, A A Hart, W J Nooyen.   

Abstract

This study presents results of investigations of lumbar and ventricular cerebrospinal fluid (CSF) biochemical markers (Beta-glucuronidase (B-gluc), Beta-2-microglobulin (B2-m), and carcinoembrionic antigen (CEA] in 28 patients with five different tumor types with leptomeningeal metastasis diagnosed by CSF cytology and/or autopsy. All received methotrexate and radiotherapy at some stage. Decadron or other symptomatic treatments were not used. Measurements of the concentrations of B-gluc, B2-m and CEA were evaluated with the aim of correlating the results of these measurements to site of disease, of monitoring response and early relapse of leptomeningeal disease, and of establishing the duration of survival. In almost all our patients the results of ventricular CSF B-gluc, B2-m and CEA measurements were lower than those obtained from lumbar CSF. The markers did not correlate with site of disease or CSF cytology. A clear relationship was found between pretreatment lumbar CSF B2-m and CEA levels, response to therapy and survival. The markers are also useful for monitoring response. The findings of this study indicate that B2-m and CEA levels have a prognostic value with regard to response to therapy and time of survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666594     DOI: 10.1007/bf00149379

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

Review 1.  Treatment of meningeal carcinomatosis.

Authors:  J P Sculier
Journal:  Cancer Treat Rev       Date:  1985-06       Impact factor: 12.111

2.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

3.  Cerebrospinal fluid beta 2-microglobulin: a study in controls and patients with metastatic and non-metastatic neurological diseases.

Authors:  A Twijnstra; A P van Zanten; W J Nooyen; A A Hart; B W Ongerboer de Visser
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

4.  Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block.

Authors:  J J Murray; F A Greco; S N Wolff; J D Hainsworth
Journal:  Am J Med       Date:  1983-08       Impact factor: 4.965

5.  Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and nonmetastatic neurological diseases.

Authors:  A Twijnstra; W J Nooyen; A P van Zanten; A A Hart; B W Ongerboer de Visser
Journal:  Arch Neurol       Date:  1986-03

6.  Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases.

Authors:  A P van Zanten; A Twijnstra; A A Hart; B W Ongerboer de Visser
Journal:  Clin Chim Acta       Date:  1986-12-30       Impact factor: 3.786

7.  Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma.

Authors:  B W Ongerboer de Visser; R Somers; W H Nooyen; P van Heerde; A A Hart; J G McVie
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

8.  Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination.

Authors:  G M Mavlight; S E Stuckey; F F Cabanillas; M J Keating; W W Tourtellotte; S C Schold; E J Freireich
Journal:  N Engl J Med       Date:  1980-09-25       Impact factor: 91.245

9.  Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin.

Authors:  T R Koch; K M Lichtenfeld; P H Wiernik
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

10.  Cerebrospinal fluid biochemical markers of central nervous system metastases.

Authors:  S C Schold; W R Wasserstrom; M Fleisher; M K Schwartz; J B Posner
Journal:  Ann Neurol       Date:  1980-12       Impact factor: 10.422

View more
  8 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

Review 2.  Leukemia and the nervous system.

Authors:  Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

3.  The clinical experience of medulloblastoma treatment and the significance of time sequence for development of leptomeningeal metastasis.

Authors:  Po-Chuan Hsieh; Chieh-Tsai Wu; Kuang-Lin Lin; Tang-Her Jaing; Chen-Kan Tseng; Tai-Ngar Lui; Shih-Ming Jung
Journal:  Childs Nerv Syst       Date:  2008-09-19       Impact factor: 1.475

4.  Contribution of CSF cytology in the diagnostic work-up of breast cancer patients with neurological symptoms: a retrospective analysis over two decades.

Authors:  C A P Wauters; J Poelen; I Mulder; D Venderink; L J A Strobbe; P Wesseling
Journal:  J Neurooncol       Date:  2012-01-04       Impact factor: 4.130

Review 5.  Leukemic and lymphomatous meningitis: incidence, prognosis and treatment.

Authors:  Marc C Chamberlain; Craig Nolan; Lauren E Abrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 6.  Neoplastic meningitis.

Authors:  Ana Aparicio; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 7.  Leptomeningeal metastases.

Authors:  Alexis Demopoulos
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 8.  Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood.

Authors:  J Hildebrand
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.